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Edited by Sandro SonninoAbstract Antiphospholipid antibodies found in antiphospholipid
syndrome are autoantibodies to phospholipid-binding proteins,
such as b2-glycoprotein I (b2GPI). We have previously reported
that among these antibodies, the so-called lupus anticoagulants
(LAs) augment b2GPI binding to the phospholipid membrane
surface, which is associated with the pathological action of
LAs. However, the molecular mechanisms underlying this aug-
mentation are uncertain. Here we show that b2GPI, which is
monomeric in solution, self-interacts at the interface of soluble
and surface-bound molecules. In addition, this self-interaction
is enhanced by LA-positive, but not LA-negative, anti-b2GPI
monoclonal antibodies. This study suggests that b2GPI self-
interaction upon surface binding could be involved in the LA-in-
duced potentiation of b2GPI binding to the phospholipid surface.
Structured summary:
MINT-6743767:
beta2GPI (uniprotkb:P02749) binds (MI:0407) to beta2GPI
(uniprotkb:P02749) by surface plasmon resonance (MI:0107)
MINT-6743776:
beta2GPI (uniprotkb:P02749) binds (MI:0407) to beta2GPI
(uniprotkb:P02749) by saturation binding (MI:0440)
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Phosphatidylserine1. Introduction
b2-Glycoprotein I (b2GPI), also designated as apolipopro-
tein H, is abundantly present in plasma (0.2 mg/ml), of which
40% is bound to lipoproteins. Although its physiological
functions have not been clearly elucidated, high sequence
homology across species suggests that b2GPI plays a pivotalAbbreviations: b2GPI, b2-glycoprotein I; LA, lupus anticoagulant
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doi:10.1016/j.febslet.2008.09.037physiological role. b2GPI can bind to anionic phospholipids,
which is a common principle in most of the in vitro activities
of b2GPI [1]. Since anionic phospholipids are required for
blood coagulation as well as anticoagulant reactions, b2GPI
binding to phospholipids is reported to inhibit both reactions
in vitro [2,3]. In addition, it is suggested that b2GPI plays pri-
mary and/or regulatory roles in the clearance of apoptotic cells
that expose anionic phosphatidylserine [4], or in the uptake of
oxidized low-density lipoprotein particles by macrophages [5].
Emerging attention has been focused on b2GPI ever since it
was reported that b2GPI is the actual target antigen of autoim-
mune-type antiphospholipid antibodies [1]. The antiphospho-
lipid syndrome characterized by the production of
antiphospholipid antibodies is a disorder of vascular thrombo-
sis and/or recurrent pregnancy morbidity. Clinically relevant
antiphospholipid antibodies do not bind directly to phospho-
lipids but rather to phospholipid-binding proteins including
b2GPI. The antibodies are detected with ELISA procedures
or coagulation tests. The most prevalent ELISA is that for
anticardiolipin antibodies, in which the antibodies from pa-
tient plasma recognize b2GPI bound to immobilized cardio-
lipin. Antibodies which prolong the clotting time of
phospholipid-dependent coagulation tests are referred to as lu-
pus anticoagulants (LAs). Paradoxically, LA is associated with
an increased risk for thrombosis in vivo, and it is noteworthy
that anticardiolipin (=anti-b2GPI) antibodies with LA activity
are reported to be most associated with thrombotic risk [1].
Previously, we and others demonstrated that LA-positive,
but not LA-negative, anti-b2GPI antibodies enhance b2GPI
binding to phospholipids and form antigen–antibody clusters
on the phospholipid membrane surface, thereby amplifying
the intrinsic anticoagulant activity of b2GPI in phospholipid-
dependent in vitro coagulation tests [6–8]. Based on these ﬁnd-
ings, it could be envisioned in vivo that the antigen–antibody
clusters induce thrombosis by impeding the anticoagulant
function of activated protein C [3], inducing cell activation
[9], or disrupting an anticoagulant annexin A5 crystal shield
on the surface of phospholipid membranes [10]. However,
the molecular mechanisms by which LA antibodies enhance
b2GPI binding to phospholipids and induce the clusters on
the phospholipid membrane surface are still poorly under-
stood. This study was undertaken to test the hypothesis that
b2GPI becomes self-interacted upon surface binding and LAs
potentiate this b2GPI self-interaction, thereby enhancing
b2GPI binding to phospholipid membranes.ation of European Biochemical Societies.
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Fig. 1. Surface plasmon resonance analysis of the interaction between
solution-phase and immobilized b2GPI. (A) Varying concentrations (1,
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2.1. Materials
b2GPI was isolated from normal human sera as described previously
[7]. BSA (essentially fatty acid- and globulin-free) and chicken egg oval-
bumin (5· crystallized) were purchased from Sigma and Seikagaku Ko-
gyo (Tokyo, Japan), respectively. Protein molecular weight markers
were from Amersham Pharmacia Biotech. Monoclonal antibodies
(Cof-18–23) were established from BALB/c mice immunized with hu-
man b2GPI and puriﬁed as reported previously [7,11,12]. The epitopes
for these antibodies were mapped using several deleted mutant mole-
cules of b2GPI produced by a baculovirus/insect cell expression system
[7,12]. Sonicated phospholipid vesicles were prepared using phosphati-
dylcholine andphosphatidylserine at amolar ratio of 1:1 as described [7].
2.2. Surface plasmon resonance
The surface plasmon resonance measurements were performed on a
BIAcore 2000 instruments at 25 C with a 20 ll/min ﬂow rate. Highly
puriﬁed b2GPI in 10 mM acetate buﬀer, pH 5.0, at a concentration of
50 lg/ml was covalently immobilized to the dextran matrix of the CM5
sensor chip via its primary amine groups at a ﬂow rate of 10 ll/min.
Excess sites were blocked with ethanolamine. Under the same condi-
tions, ovalbumin and BSA were also immobilized on the sensor chip
as negative controls. Then, b2GPI solution was injected as analyte over
immobilized b2GP1, ovalbumin or BSA in 10 mM HEPES, 0.15 M
NaCl, 3 mM EDTA and 0.005% P20 surfactant (pH 7.4). An activated
and blocked ﬂow-cell without immobilized ligand was used to evaluate
non-speciﬁc binding. All sensorgrams were corrected by subtracting
the background runs of b2GPI over this ﬂow-cell from corresponding
runs of b2GPI over ﬂow-cells with immobilized proteins and analyzed
using BIAevaluation Software version 3.0 based on the so-called Mar-
quardt–Levenberg algorithm. The sensorgrams were analyzed by glob-
ally ﬁtting both the association and dissociation phases for all
concentrations simultaneously. The degree of randomness of residual
plots and the reduced chi-square (v2) values were used to determine
the goodness of the ﬁtting. Response plateau values (Req), which were
obtained by a non-linear least square ﬁt of the association curves, were
plotted versus the concentrations of b2GPI. The curve was analyzed
using the equation describing the single-site equilibrium binding to
generate the equilibrium dissociation constant (KD).
2.3. b2GPI binding to immobilized b2GPI or Cof-18
Puriﬁed b2GPI was labeled with Na
125I as described [7]. The speciﬁc
activity of labeled b2GPI (
125I-b2GPI) was 1.8 · 105 cpm/pmol. Unla-
beled b2GPI (5 lg/ml) or Cof-18 (5 lg/ml) was immobilized on micro-
plate wells (Sumilon C-type Sepaplate, Sumitomo Bakelite Co., Ltd.,
Japan) by incubating 100 ll of TBS containing b2GPI or Cof-18 for
12 h at room temperature. After washing three times with 0.1%
Tween/TBS, the wells were blocked by the addition of 250 ll TBS con-
taining 4% BSA (TBSB) for 2 h at 37 C. After aspiration, various con-
centrations of 125I-b2GPI (0–360 nM) in 100 ll TBS were added and
incubated for 1 h at 37 C. For determination of non-speciﬁc binding,
10-fold molar excess of unlabeled b2GPI was included in the solution.
Wells were then washed three times with TBS before counting in a c-
counter (ARC 6000, Aloka, Tokyo, Japan). Speciﬁc binding of 125I-
b2GPI to immobilized b2GPI was determined by subtracting the
non-speciﬁc binding of 125I-b2GPI from the total binding. In separate
experiments, the binding of solution-phase 125I-b2GPI to immobilized
b2GPI was examined in the presence of each monoclonal antibody
(Cof-18–23; 150 nM).
2.4. Eﬀect of ionic strength
b2GPI and phospholipid vesicles were coated onto microplates as
described above and elsewhere [7]. The plates were incubated with
125I-b2GPI (80 nM) in Tris-buﬀer containing various concentrations
of NaCl (0–1 M) for 1 h at 37 C.2, 4, 8 and 12 lM) of b2GPI were injected for 2 min over the b2GPI
immobilized sensor chip at a ﬂow rate of 20 ll/min. The beginning of
the association and dissociation phases is marked by long and short
arrows, respectively. (B) Under the same conditions, b2GPI (1, 2, 4, 8
or 12 lM) was injected over immobilized BSA or ovalbumin surface.
(C) The steady state values at every diﬀerent concentration being
considered the Req (response at equilibrium) were plotted against the
b2GPI concentrations.3. Results and discussion
3.1. Surface plasmon resonance analyses
The size of plasma-puriﬁed b2GPI, as determined by sedi-
mentation equilibrium measurements, is consistent with amonomer [13]. In addition, gel ﬁltration of b2GPI in our prep-
aration gave a symmetrical protein peak corresponding to
monomeric b2GPI regardless of the protein concentration
(up to 5 mg/ml) loaded onto the column (Supplementary
Fig. 1), thus showing that this protein is indeed monomeric
in solution. We used a BIAcore biosensor to examine the
real-time binding of soluble b2GPI to immobilized b2GPI.
For the immobilization of b2GPI on the sensors surface, the
injection of b2GPI was controlled to obtain a response of
approximately 900 response units (RU), corresponding to
1.1 ng/mm2 of the immobilized protein. As negative controls,
BSA and ovalbumin were immobilized to about 1000 RU
(1.2 ng/mm2) and 600 RU (0.7 ng/mm2), respectively. Solu-
tion-phase b2GPI at concentrations ranging from 1 to 12 lM
was injected over the immobilized b2GPI surface (Fig. 1A).
The sensorgrams showed a progressive increase in response
units with increasing concentrations of solution-phase b2GPI.
3310 A. Hayashi et al. / FEBS Letters 582 (2008) 3308–3312Immobilized BSA or ovalbumin showed no signiﬁcant interac-
tions with b2GPI (Fig. 1B).
The sensorgrams for diﬀerent concentrations of b2GPI
(Fig. 1A) were analyzed by globally ﬁtting both the association
and dissociation phases simultaneously. The binding data were
ﬁtted with various kinetic models including Langmuir 1:1
binding, heterogeneous-analyte, bivalent analyte, heteroge-
neous-ligand and two state binding models. However, the ﬁt-
ting quality evaluation using v2 and residual values showed
no binding model was suﬃcient to describe the interaction,
thereby suggesting that b2GPI–b2GPI binding process might
be composed of complex, multistep interactions such as post-
binding conformational change, post-binding aggregation,
and multivalent avidity eﬀects.
In order to determine the dissociation constant (KD) for a
steady state binding between solution-phase and immobilized
b2GPI, equilibrium binding level was plotted versus the con-
centration of b2GPI in solution (Fig. 1C), and ﬁtted with the
single-site equilibrium binding model. The KD thus calculated
was 8.0 · 106 M. Alternatively, curves derived from 4, 8 and
12 lM of b2GPI exhibited good individual ﬁts to the Langmuir
model and could be therefore subjected to KD determination
individually. The KD values thus determined were 4.6 · 107,
1.4 · 106 and 1.8 · 106 M for 4, 8 and 12 lM, respectively.3.2. Solution-phase b2GPI binding to b2GPI immobilized on
microplate wells
In another experiment, we observed that 125I-b2GPI bound
to b2GPI immobilized on microplate wells in a dose-dependent
manner (Fig. 2A). The binding was not saturated in the exam-
ined concentration range of 125I-b2GPI, but was signiﬁcant
compared with very little binding of 125I-b2GPI to ovalbu-
min-coated wells (used as a negative control, Fig. 2A). To
determine whether radiolabeling altered the aﬃnity of
b2GPI, a mixture of unlabeled and labeled b2GPI (0.8 mg/ml
and 0.2 mg/ml, respectively) was loaded onto the gel ﬁltration0
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Fig. 2. 125I-labeled b2GPI binding to immobilized b2GPI. (A) Puriﬁed b2G
plates, and then various concentrations of 125I-labeled b2GPI were added. A
(80 nM) containing various concentrations of NaCl (0–1000 mM) was adde
phosphatidylcholine at a molar ratio of 1:1). The plates were then washed acolumn. A symmetrical protein peak with radioactivity corre-
sponding to monomeric b2GPI was obtained, suggesting no
interaction of 125I-b2GPI and b2GPI in solution (Supplemen-
tary Fig.1). Cof-18, an anti-b2GPI monoclonal antibody
[7,11] was immobilized on microplate wells and 125I-b2GPI
binding to Cof-18-coated wells was examined. As expected
from the aﬃnity constant (2.5 nM1) between b2GPI and
Cof-18 [7], the binding reached saturation (open circles in
Fig. 2A) in the examined concentration range of 125I-b2GPI
(22.5–360 nM). This saturable binding suggests that solution-
phase b2GPI does not bind to b2GPI captured by the antibody.
These results indicate that soluble b2GPI can bind to surface-
bound b2GPI, for which conformational change in b2GPI in-
duced upon surface binding may be important.3.3. Eﬀect of ionic strength
As previously reported [14], b2GPI binding to phospholipid
membranes is mediated mainly by the electrostatic interac-
tions. To address whether the electrostatic interaction also
contributes to the self-interaction, we examined the b2GPI
binding to immobilized b2GPI at NaCl concentrations of 0–
1 M (Fig. 2B). Increased ionic strength remarkably inhibited
the b2GPI binding to immobilized phospholipids (phosphati-
dylserine:phosphatidylcholine = 1:1; mol/mol), but much less
aﬀected the b2GPI binding to immobilized b2GPI. The results
suggested little contribution of electrostatic interaction in
b2GPI self-interaction.
Since the structure of surface-bound b2GPI is suggested to
diﬀer from that of soluble b2GPI [11,15–21], the region(s) for
intermolecular self-association, which may be hydrophobic
(Fig. 2B), is presumably exposed upon surface binding of
b2GPI.3.4. Eﬀects of anti-b2GPI monoclonal antibodies
Anti-b2GPI monoclonal antibodies Cof-20, Cof-21, and
Cof-22 were previously revealed to have LA activity and0
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Fig. 3. Eﬀect of LA-positive anti-b2GPI monoclonal antibodies on the binding of
125I-b2GPI to immobilized b2GPI. To the b2GPI-coated
microplate, 100 ll of TBS solution containing various concentrations of 125I-b2GPI was added and incubated for 1 h at 37 C. After washing,
radioactivity in each well was counted in a c-counter. (A) Non-speciﬁc binding (n) was determined in the presence of 10-fold molar excess of
unlabeled b2GPI. Speciﬁc binding (s) was calculated by subtracting non-speciﬁc binding from total binding (d). (B–D) In the presence of 150 nM
each monoclonal antibody Cof-20 (B), Cof-21 (C), or Cof-22 (D), total (d) and non-speciﬁc bindings (n) was determined and speciﬁc binding (s) was
calculated as described above.
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Fig. 4. Eﬀect of LA-negative anti-b2GPI monoclonal antibodies on
the binding of 125I-b2GPI to immobilized b2GPI. To the b2GPI-coated
microplate, 100 ll of TBS solution containing various concentra-
tions of 125I-b2GPI in the absence (d) or presence of 150 nM each
monoclonal antibody Cof-18 (s), Cof-19 (n), or Cof-23 (h) was
added.
A. Hayashi et al. / FEBS Letters 582 (2008) 3308–3312 3311potentiate b2GPI binding to phospholipids [7]. The speciﬁc
125I-b2GPI binding to immobilized b2GPI (Fig. 3A) was also
enhanced by these antibodies (Fig. 3B–D). On the other hand,
Cof-19 and Cof-23, which are LA-negative anti-b2GPI mono-
clonal antibodies and do not aﬀect the b2GPI binding to phos-
pholipids [7], did not aﬀect the self-interaction of soluble and
surface-bound b2GPI (Fig. 4). Cof-18, which was previously
shown to recognize domain V of b2GPI and to inhibit b2GPI
binding to phospholipids [7], signiﬁcantly inhibited the self-
association of soluble and surface-bound b2GPI (Fig. 4). This
ﬁnding suggests that domain V contains (at least one of) the
self-association sites that may partially overlap the phospho-
lipid-binding site. The carboxy-terminal ﬂexible loop in do-
main V, which plays roles in binding to phospholipid
membranes and hydrophobic ligands [14], may be a candidate
for one of the self-interaction sites.
Anti-b2GPI antibodies from patients of the antiphospho-
lipid syndrome are generally unable to bind b2GPI in solution
but do bind b2GPI immobilized on an ELISA plate [22]. There
are two models for the binding of anti-b2GPI autoantibodies
to surface-bound b2GPI. Firstly, the induction of a conforma-
tional change in b2GPI by its surface binding results in the
exposure of cryptic epitopes for these antibodies. Secondly, be-
cause these antibodies are of intrinsically low-aﬃnity, they can
bind b2GPI when a certain high density of b2GPI immobilized
3312 A. Hayashi et al. / FEBS Letters 582 (2008) 3308–3312on an ELISA plate is achieved; one antibody must bind two
closely spaced b2GPI to obtain considerable avidity. Based
on the present results, an alternative model that combines
two models can be presented; a conformational change of
b2GPI induced after its binding to ELISA plate promotes
b2GPI self-association, and then dimeric quaternary structures
may be recognized as neo-epitopes, or clustering of antigenic
sites allow the bivalent binding of otherwise low-aﬃnity anti-
bodies.
In conclusion, the results of this study corroborate the
hypothesis that b2GPI may self-interact upon surface binding.
In addition, this self-interaction is enhanced by LA-positive,
but not LA-negative, anti-b2GPI monoclonal antibodies, thus
suggesting that b2GPI self-interaction and its enhancement by
LAs might be involved in the molecular mechanisms underly-
ing the LA-induced augmentation of b2GPI binding to the
phospholipid membrane surface.Appendix A. Supplementary material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2008.
09.037.
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